
    
      The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to
      CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL)
      patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel
      out of specification for commercial release where no overwhelming safety concerns has been
      identified for manufacture and release of the out of specification product.
    
  